

Galveston National Laboratory Galveston TX 77555-0610

08-Feb-2021

# **PROJECT #74908**

The efficacy assessment of new compound against SARS-CoV-2 infection in *in vitro* models The Test Article *Protefl* (alias Proteflazidum or "Compound-1\_JVergar"). A Flavonoid Composition from plants Deschampsia cetspitosa L. and Calamagrostis epigeios L. (both of the Poaceae = Gramineae Family), 1000 ug/ml in 74% Ethanol. Manufacturing Unit: Ecopharm (Ukraine).

Test article provided by Data Management Med High-Tech GmbH (Wiesbaden, Germany) was used to test antiviral properties against SARS-CoV-2 infection in two *in vitro* models.

# SARS-CoV-2 inhibition by a cell-based assay

A slightly modified standard live virus-based microneutralization (MN) assay was used to rapidly evaluate the article efficacy against SARS-CoV-2 infection in *African green monkey* kidney (Vero E6) and adenocarcinomic human alveolar basal epithelial stably expressing human ACE2 receptor (A549/ACE2) cell cultures. Confluent Vero E6 and A549/ACE2 cells grown in 96-wells microtiter plates were pre-treated with serially 2-folds diluted article in duplicate over four concentrations for 2-, 0.5- or 0- hours before infection with ~100 and ~500, respectively, infectious SARS-CoV-2 (USA\_WA-1/2020 isolate) particles in 100 µL EMEM supplemented with 2% fetal bovine serum (FBS). Vero E6 and A549 cells treated with parallelly diluted Vehicle with or without virus were included as positive and negative controls, respectively. After cultivation at 37 °C for 3- (Vero E6) or 4- (A549/ACE2) days, individual wells were observed

**GALVESTON NATIONAL LABORATORY** 



Galveston National Laboratory Galveston TX 77555-0610 08-Feb-2021

under the microcopy for the status of virus-induced formation of cytopathic effect (CPE). The efficacy of tested article was calculated and expressed as the lowest concentration capable of completely preventing virus-induced CPE in 100% of the wells. The toxicity to the treated cells was assessed by observing floating cells and altered morphology of adhered Vero E6 and A549 cells in wells under the microcopy. All work with SARS-CoV-2 was performed in the biosafety level 3 (BSL-3) facility of the Galveston National Laboratory.

## Data interpretation

T – cytotoxic effect. Protection against SARS-CoV-2 infection cannot be assessed because of cytotoxic effect. To test the efficacy, the article's formulation needs to be modified.

**ND** – no CPEs detected. The article at the tested concentration shows 100% protection against SARS-CoV-2 infection.

**Single CPEs** – only 1-3 CPEs detected. The article at the tested concentration shows partially protection against SARS-CoV-2 infection. There is a possibility that the higher concentration of tested article can increase protection level.

**Slightly T/ ND** - no CPEs detected, however, tested article produces slightly cytotoxic effect. The article at the tested concentration shows 100% protection against SARS-CoV-2 infection, however, slightly morphological changes in cell culture are observed which can affect infection.

**GALVESTON NATIONAL LABORATORY** 

UTMB CENTER FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES • SEALY CENTER FOR VACCINE DEVELOPMENT WORLD HEALTH ORGANIZATION COLLABORATING CENTER FOR TROPICAL DISEASES UTMB CENTER FOR HEPATITIS RESEARCH • MCLAUGHLIN ENDOWMENT FOR INFECTION AND IMMUNITY 301 UNIVERSITY BOULEVARD, GALVESTON, TEXAS 77555-0610 (409) 266-6500 FAX (409) 266-6810



Galveston National Laboratory Galveston TX 77555-0610

08-Feb-2021

Note: To confirm protection level of tested article:

- 1. Modify article formulation (using lover concentration of Ethanol or different Vehicle)
- 2. Test different in vitro model Calu-3 (2B4)

Sincerely,

ant mus

Chien-Te Kent Tseng, Ph.D. Professor, Department of Microbiology and Immunology Director, SARS/MERS/COVID-19 P3 Laboratory 301 University Boulevard Galveston, TX 77555-0609 5.200Q Galveston National Laboratory (GNL) 0 409.266.6929 F 409.747.0762 Lab 409.266.6587 E sktseng@utmb.edu W www.utmb.edu W http://microbiology.utmb.edu/faculty/tseng.shtml

elit ACE

Aleksandra K. Drelich, Ph.D. Project Principal Investigator, Department of Microbiology and Immunology <sup>301</sup> University Boulevard Galveston, TX 7755-0609 6.324 Galveston National Laboratory (GNL) 0 409.266.6572 Lab 409.266.6587 E aldrelic@utmb.edu

### **GALVESTON NATIONAL LABORATORY**

UTMB CENTER FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES • SEALY CENTER FOR VACCINE DEVELOPMENT WORLD HEALTH ORGANIZATION COLLABORATING CENTER FOR TROPICAL DISEASES UTMB CENTER FOR HEPATITIS RESEARCH • MCLAUGHLIN ENDOWMENT FOR INFECTION AND IMMUNITY 301 UNIVERSITY BOULEVARD, GALVESTON, TEXAS 77555-0610 (409) 266-6500 FAX (409) 266-6810

#### Project # 74098 Data Management Med-High-Tech GmbH *in vitro* prelimenary studies

